سجلت شركة Hims & Hers Health إيرادات أقل من التوقعات في الربع الأول وسط ضغوط على هوامش الربح.
تتحول الشركة بعيدًا عن أدوية GLP-1 المركبة نحو شراكات تجارية مع شركتي Novo Nordisk وEli Lilly. ومن المتوقع أن يؤثر هذا التغيير على هوامش الربح في المدى القريب مع تقليل المخاطر القانونية المرتبطة بالتركيبات الدوائية.
Hermès reported a 6% revenue increase in the first quarter of 2026, driven entirely by higher prices amid flat volume growth. The Middle East conflict led to a 6% sales drop in that region and a double-digit decline in its US-traded shares. Analysts view the sell-off as overdone, presenting a buying opportunity for long-term investors.
من إعداد الذكاء الاصطناعي
HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.
Palantir Technologies Inc. delivered exceptional first-quarter results, with revenue exceeding consensus estimates by 6% and earnings per share nearly 20% above forecasts. The company's revenue grew over 80% year-over-year, outpacing most tech peers. Despite the strong performance, shares did not rally amid valuation concerns.
من إعداد الذكاء الاصطناعي
LVMH announced first-quarter sales rose 1% organically to €19.12 billion. Fashion and leather goods sales fell 2% to €9.25 billion, better than the prior quarter but below expectations. The Middle East conflict impacted growth by about 1 percentage point.